These findings supported the idea that 1,25(OH)2D3 likely inhibited the expression of RANKL through reducing the synthesis and secretion of TNF-α, IL-17, and IL-6 in RA patients' PBMCs, which eventually decreased bone erosion. This evidence concerns the gene IL17A and rheumatoid arthritis.